For research use only. Not for therapeutic Use.
WS6 (Cat.No:I001618) is a potent and selective small molecule inhibitor with promising therapeutic potential. It targets kinases and modulates cellular signaling pathways, offering new avenues for drug development in various diseases. Extensive research is ongoing to understand its mechanism of action and explore its applications in medicine.
| Catalog Number | I001618 |
| CAS Number | 1421227-53-3 |
| Synonyms | N-[6-[4-[2-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)anilino]-2-oxoethyl]phenoxy]pyrimidin-4-yl]cyclopropanecarboxamide |
| Molecular Formula | C29H31F3N6O3 |
| Purity | ≥95% |
| Target | IκB/IKK |
| Solubility | DMSO 20 mg/ml |
| Storage | Store at -20°C |
| IUPAC Name | N-[6-[4-[2-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)anilino]-2-oxoethyl]phenoxy]pyrimidin-4-yl]cyclopropanecarboxamide |
| InChI | InChI=1S/C29H31F3N6O3/c1-37-10-12-38(13-11-37)17-21-6-7-22(15-24(21)29(30,31)32)35-26(39)14-19-2-8-23(9-3-19)41-27-16-25(33-18-34-27)36-28(40)20-4-5-20/h2-3,6-9,15-16,18,20H,4-5,10-14,17H2,1H3,(H,35,39)(H,33,34,36,40) |
| InChIKey | FTODTDQFHDJWIQ-UHFFFAOYSA-N |
| SMILES | CN1CCN(CC2=CC=C(NC(CC3=CC=C(OC4=CC(NC(C5CC5)=O)=NC=N4)C=C3)=O)C=C2C(F)(F)F)CC1 |
| Reference | 1:Endocr J. 2015;62(4):379-86. doi: 10.1507/endocrj.EJ14-0449. Epub 2015 Mar 11. WS6 induces both alpha and beta cell proliferation without affecting differentiation or viability.Boerner BP,George NM,Mir SU,Sarvetnick NE, PMID: 25739404 PMCID: PMC4876955 DOI: 10.1507/endocrj.EJ14-0449 </br><span>Abstract:</span> Agents that stimulate human pancreatic beta cell proliferation are needed to improve diabetes mellitus treatment. Recently, a small molecule, WS6, was observed to stimulate human beta cell proliferation. However, little is known about its other effects on human islets. To better understand the role of WS6 as a possible beta cell regenerative therapy, we carried out in-depth phenotypic analysis of WS6-treated human islets, exploring its effects on non-beta cell proliferation, beta cell differentiation, and islet cell viability. WS6 not only stimulated beta cell proliferation in cultured human islets (in agreement with previous reports), but also human alpha cell proliferation, indicating that WS6 is not a beta cell-specific mitogen. WS6 did not change the proportion of insulin-positive beta cells or the expression of beta cell-specific transcription factors, suggesting that WS6 does not alter beta cell differentiation, and WS6 had no effect on human islet cell apoptosis or viability. In conclusion, WS6 stimulates proliferation of both human beta and alpha cells while maintaining cellular viability and the beta cell differentiated phenotype. These findings expand the literature on WS6 and support the suggestion that WS6 may help increase human islet mass needed for successful treatment of diabetes. |
